[Musique] Je suis le bâtard, cette noirâtre violé. Je suis le fruit du péché entre maître et sa prétendue traîner. Yana était son nom. Chaque soir, je l'ai en train de crier. Le cri de plaisir d'une catin est soupçonné. Un jour dans le champ, son petit frère l'entendit. Il tenta de s'interposer, mais ce jour il y perdit la vie. [Musique] Et la tristesse m'envahit depuis que la justice a été vendu sur une estrade pour une question de prix. Aujourd'hui, toujours encore esclave d'une histoire itérative, je sui ...

Core Insights - SeaStar Medical Holding Corporation is focusing on the commercialization of QUELIMMUNE therapy for critically ill pediatric patients suffering from acute kidney injury (AKI) and sepsis [1][2] - The QUELIMMUNE therapy received approval in February 2024 under a Humanitarian Device Exemption, demonstrating safety and probable clinical benefit for a limited population of critically ill children [2] - The therapy aims to reduce destructive hyperinflammation that can lead to organ failure and increased mortality rates [5][6] Company Overview - SeaStar Medical is a commercial-stage healthcare company dedicated to transforming treatments for critically ill patients facing organ failure [4] - The QUELIMMUNE therapy is the only FDA-approved product for life-threatening AKI due to sepsis in critically ill pediatric patients [4] - The company has been awarded Breakthrough Device Designation for four therapeutic indications by the FDA, facilitating a faster approval process and better reimbursement dynamics [6] Therapy Details - QUELIMMUNE therapy is designed for children weighing 10 kilograms or more who are treated in the ICU with Renal Replacement Therapy (RRT) [2] - The therapy was commercially launched in July 2025, following its approval [2] - The therapy addresses the urgent need for effective treatments in pediatric patients with few options available [2][3] Clinical Context - AKI is characterized by a sudden loss of kidney function and can result from various conditions, including sepsis and severe trauma [3] - Destructive hyperinflammation associated with AKI can lead to multi-organ dysfunction and increased healthcare costs due to prolonged ICU stays and reliance on dialysis [3] - The company is conducting a pivotal trial of its Selective Cytopheretic Device (SCD) therapy in adult patients with AKI, impacting over 200,000 adults in the U.S. annually [6]

[Music] [Music] In 2015, thousands of Canadians gathered in Ottawa in front of Parliament Hill to commemorate the 100th anniversary of the 1915 Armenian genocide. They use the slogan I remember and demand not only to express the Armenian community's desire to remember the victims of the genocide, but also to demand that the world recognize the events as a genocide. Oh, that's me, by the way.I was 8 years old. I was there and ever since I've tried to go about every year, but I've noticed that every time less ...

由中山大学附属第一医院团队牵头联合美国罗格斯大学科研人员破解细胞膜的"脆弱密码"，有望为治疗 脓毒败血症等与炎症风暴相关的疾病探索新思路，该研究结果在线发表在《自然》(Nature)。 中山大学附属第一医院精准医学研究院研究员许杰11日在该院举行的新闻发布会上表示，通过调控或抑 制这个蛋白，可以在炎症发展初期把相关死亡细胞"包裹"，降低炎症风暴的发生概率，"这样给临床上 对病人的处理赢得宝贵的时间，意义重大"。 细胞膜就像保护细胞的"城墙"，维持着细胞内外环境的稳定。但当细胞遭遇外力挤压、血流冲击或组织 拉伸时，细胞膜可能破裂，并将细胞内容物(如DNA、炎性分子)倾泻而出，引发周围细胞的强烈反应。 这种被称为"质膜破裂"的现象，不仅是多种细胞死亡的最终结局，更是免疫激活、组织损伤乃至炎症风 暴的重要触发点。然而，长期以来医学界一直存在着未解问题：当机械力过强时，是什么决定了细胞膜 是否会"撕裂"？是否有专门的调控因子参与这类极端应激反应？ 为此团队对几千个人类多跨膜蛋白进行系统性敲低筛选，通过自主创新的高通量机械张力刺激设备，发 现一种名为NINJ1的跨膜蛋白在多种细胞类型中都显著影响机械张力下膜破裂的概率。 ...

Core Insights - Clearside Biomedical is advancing the delivery of therapies to the back of the eye through its proprietary suprachoroidal space (SCS) injection platform, which will be highlighted at the upcoming Clinical Trials at the Summit (CTS) Meeting [1][2] Company Overview - Clearside Biomedical, Inc. is a biopharmaceutical company focused on improving patient outcomes by utilizing its SCS injection platform for targeted delivery of therapies to treat sight-threatening eye diseases [7] - The company’s lead product, CLS-AX (axitinib injectable suspension), is in development for neovascular age-related macular degeneration (wet AMD) and is preparing for a Phase 3 program [7] Technology and Innovation - The SCS Microinjector is a patented device that allows for in-office, repeatable, non-surgical procedures to deliver a variety of therapies directly to the macula, retina, or choroid [5][7] - CLS-AX is designed as a longer-acting therapy that achieves pan-VEGF blockade, potentially offering advantages over existing anti-VEGF therapies by targeting different levels of the angiogenesis cascade [4][5] Clinical Development - The company is showcasing multiple presentations related to its SCS delivery platform and its development partners at the CTS Meeting, including updates on CLS-AX for neovascular AMD and ABBV-RGX-314 for diabetic retinopathy [3][4] - Early clinical trials for CLS-AX have shown it to be well tolerated with a positive safety profile, indicating its potential for prolonged duration and targeted delivery [4]

编译丨王聪 编辑丨王多鱼 排版丨水成文 总的来说，该研究证实了 NINJ1 是膜生物力学特性的真正决定因素， 还表明了 在不同机械微环境的组织中，质膜破裂受到 NINJ1 表达差异和外部机械力的精细 调控。 论文链接 ： 质膜的完整性对于细胞功能的几乎所有方面都至关重要。 机械力 可导致质膜受损，但尚不清楚是否存在大分子在机械应变下调控质膜的完整性。 2025 年 6 月 9 日，中山大学第一附属医 院 许杰 、 向芙莉 、新泽西州立大学 Zheng Shi 及北京生命科学研究院 邵峰 院士等，在国际顶尖学术期刊 Nature 发 表了题为 ： NINJ1 regulates plasma membrane fragility under mechanical strain 的研究论文。 在这项最新研究中，研究团队构建了一个 384 孔细胞拉伸系统，能够对培养细胞施加精确且可重复的拉伸力。利用该系统，研究团队使用 10843 种 siRNA 以靶 向筛选 2726 种多重跨膜蛋白，以检测拉伸诱导的膜通透性变化。 该筛选结果将 NINJ1 蛋白质列为首要发现，该蛋白质最近被发现可调控细胞焦亡及其他溶解性细胞死亡 ...

Amphastar Pharmaceuticals (AMPH) 2025 Conference June 05, 2025 02:00 PM ET Speaker0 Good afternoon and welcome to day two of the Jefferies Global Healthcare Conference. My name is Dennis Ding, biotech analyst here. I have the great pleasure of having Amphastar Pharmaceuticals here up with me for fireside chat. We have CFO Bill Peters as well as the EVP of Corporate Administration Jacob Liawatadui, here with us. Welcome. Speaker1 Thank you. Thank you. Speaker0 So maybe to kick things off, like, don't you giv ...

Stevanato Group (STVN) 2025 Conference June 05, 2025 10:30 AM ET Speaker0 Jeff there we go. Hi. Good morning. Dave Windley with Jefferies Healthcare Equity Research. Appreciate your attendance and and interest in our conference twenty twenty five. We are on kind of the homestretch here on Thursday. Our presenting company for this session is Stevanato Group. Here to present for them is the company's CEO, Franco Sveinato. So he has just a few slides and is going to give some prepared remarks to kick off and t ...

Core Insights - Babcock Injury Lawyers has released a new book titled "A Life-Changing Accident," authored by the firm's founder, Stephen Babcock, which is now ranking in multiple Amazon legal categories since its publication [2][3] Group 1: Book Overview - The book provides an overview of the challenges faced by accident victims during recovery and legal proceedings, reflecting the firm's commitment to enhancing public access to legal knowledge [3][4] - It aims to simplify complex legal concepts for readers unfamiliar with the personal injury process, explaining key legal stages from the occurrence of an accident to the resolution of a claim [4][5] - The content is designed for general audiences, particularly recent accident victims, and includes general legal information and real-world examples to help readers understand their rights and options [5][6] Group 2: Firm's Educational Efforts - The publication of "A Life-Changing Accident" is part of Babcock Injury Lawyers' broader efforts to support injury victims through legal representation and educational outreach [6] - The firm has historically utilized blog posts and digital resources to inform the public about relevant legal topics, and this book marks its first extended-format publication [6][7] - Babcock Injury Lawyers is committed to transparency and client education, providing legal support to help individuals navigate complex legal challenges [7]

Core Insights - New data from clinical studies support the subcutaneous administration of Sarclisa via an on-body injector, demonstrating non-inferior efficacy and safety compared to intravenous infusion [1][5][6] Group 1: Clinical Study Findings - The IRAKLIA phase 3 study showed very good partial response (VGPR) rates of 46.4% for Sarclisa SC-Pd and 45.9% for Sarclisa IV-Pd, indicating non-inferiority [5] - The objective response rate (ORR) for Sarclisa SC-Pd was 71.1% compared to 70.5% for Sarclisa IV-Pd, establishing non-inferiority [7] - The overall safety profile of Sarclisa SC-Pd was consistent with Sarclisa IV-Pd, with a lower rate of systemic infusion reactions (1.5% vs. 25%) [12][8] Group 2: Patient Experience and Administration - The on-body injector (OBI) is expected to enhance patient experience by providing greater convenience and flexibility, leading to higher patient satisfaction scores [2][9] - 70% of patients treated with Sarclisa SC-Pd reported satisfaction with their injection, compared to 53.4% in the IV-Pd group [12] - The OBI allows for a hands-free administration process, potentially reducing the physical burden on healthcare providers [2][11] Group 3: Future Directions and Regulatory Submissions - Data from the IRAKLIA and IZALCO studies will form the basis for global regulatory submissions for Sarclisa SC administration [6][14] - Sanofi is also exploring Sarclisa SC administration in front-line treatment settings through additional studies [14] - The IRAKLIA study's abstract was selected for the 2025 Best of ASCO program, highlighting its significance in the field [14]